Desloratadine

Quick links to important sections

Desloratadine

Selected form

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Desloratadine

Quick Facts

Property Description
Active Ingredient (INN) Desloratadine
Form Tablet, Oral Solution, Syrup
Pharmacological Class Second-Generation Antihistamine
General Purpose Anti-allergic agent (Histamine H1-receptor antagonist)
Origin Synthetic (Metabolite of Loratadine)

What Type of Medicine is Desloratadine and Why Does it Matter?

Desloratadine is classified as a potent, long-acting second-generation antihistamine that acts as a selective H1-receptor antagonist. It is the primary active metabolite of the older antihistamine, Loratadine, chemically known as Descarboethoxyloratadine. This metabolic status means the substance is already in its fully active form upon administration.

Its classification as a second-generation compound is a significant differentiating factor, due to its reduced ability to enter the central nervous system. This ensures that the symptomatic relief is targeted primarily at peripheral tissues without causing the sedation or drowsiness commonly associated with older, first-generation antihistamines. This lack of sedation is a major advantage for patients seeking relief while maintaining normal daily function.

Composition, Formulations, and General Anti-Allergic Purpose

As an INN (International Nonproprietary Name), Desloratadine is the sole active ingredient in various formulations. These single-ingredient products are available in multiple dosage forms suitable for oral administration, including the standard film-coated tablet, the orally disintegrating tablet, and liquid formulations like the oral solution or syrup.

The fundamental purpose of Desloratadine is to counteract the effects of histamine, the substance the body releases during an allergic reaction. Through potent H1-receptor blockade, Desloratadine prevents histamine from binding to receptors in the body's tissues. This mechanism effectively controls allergic symptoms by interrupting the body's response cascade, providing general benefit by diminishing symptoms like itching and fluid discharge.

Regulatory References

  1. EMA Aerius (Desloratadine) EPAR

What side effects are possible with Desloratadine?

Possible Side Effects and Safety Information

This section outlines the adverse reactions and safety characteristics of desloratadine, based strictly on official governmental regulatory documents, such as the FDA Prescribing Information and the EMA Summary of Product Characteristics (SmPC).


Documented Adverse Reactions

Adverse effects are categorized by frequency, which is determined from clinical trial data and post-marketing surveillance:

Frequency Classification Examples of Documented Adverse Reactions
Common (1% to < 10%) Headache, Fatigue (tiredness), Dry mouth
Very Rare (< 0.01%) Seizures, Hallucinations, Hepatitis, Jaundice, Anaphylaxis, Tachycardia
Not Known Increased appetite, Weight increased, Abnormal behaviour, QT prolongation

Adverse events are also grouped by System-Organ Class (SOC), including Nervous System Disorders (e.g., dizziness, insomnia), Gastrointestinal Disorders (e.g., nausea, dyspepsia), and Hepatobiliary Disorders.


Serious Safety Considerations

Serious Adverse Reactions officially documented, primarily from post-marketing reports, include severe hypersensitivity reactions like Anaphylaxis and Angioedema, as well as Hepatitis, Jaundice, and Seizures.

Safety-Related Restrictions

Official regulatory documents note several constraints:

  • Contraindication: Documented hypersensitivity to the active substance, any excipients, or to Loratadine (the parent compound).
  • Population-Specific Caution: Caution is advised when used in patients with severe hepatic or renal impairment. Specific caution is also advised for young children and individuals with a personal or family history of seizures due to a documented risk of new-onset seizures.

The safety profile is formally structured to communicate the spectrum of risks, from common to rare events, and to define safety limitations for specific patient groups and pre-existing conditions.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents define the Desloratadine overdose profile by noting that the adverse event profile is similar to that seen with therapeutic doses, but the magnitude of the effects can be higher. Documented manifestations reported in high-dose trials include central nervous system effects such as drowsiness and somnolence.

Immediate medical attention is required for signs of severe systemic involvement. Call emergency services immediately if the individual has a seizure, experiences trouble breathing, or can't be awakened. Post-marketing reports for the pediatric population have noted serious cardiovascular events, including QT prolongation, arrhythmia, and bradycardia, which highlights specific areas of concern.

In managing an overdose, symptomatic and supportive treatment is recommended. Regulatory labeling confirms that no specific antidote is known. The substance is resistant to certain procedural interventions, as Desloratadine and its active metabolite are not eliminated by hemodialysis. Management is therefore concentrated on supportive care and considering measures to remove unabsorbed substance.

Therapeutic Uses of Desloratadine

Main Uses and Benefits of Desloratadine

Desloratadine is commonly used across conditions characterized by periods of heightened symptoms related to specific allergic manifestations. The relevant therapeutic domains include:

It may assist with managing symptoms related to systemic imbalance that interfere with daily comfort in conditions such as seasonal allergic rhinitis, perennial allergic rhinitis, and Chronic Idiopathic Urticaria (Hives). This use may assist with maintaining functional stability.

This medication is typically utilized to help with symptoms that create noticeable physiological strain. This supportive role is particularly relevant in contexts involving heightened systemic burden.

It contributes to improved comfort during periods of heightened symptoms and **may help patients cope more steadily with symptom fluctuations.


Quick Fact: Supports general well-being during symptomatic phases


Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Desloratadine?

Eligibility to use Desloratadine is strictly defined by governmental regulatory documentation, outlining specific populations that are approved, restricted, or prohibited from using the medicine. This information does not constitute medical advice and is based solely on official prescribing labels.


Populations Approved and Age-Related Eligibility

Population Group Eligibility Status (Regulatory Labeling)
Adults and Adolescents Approved for individuals 12 years of age and older (tablets/syrup).
Pediatric Use (Liquid) Established for children ge 6 months of age for specific indications (e.g., chronic urticaria).
Infants Safety and efficacy have not been established for infants under 6 months of age.

Absolute Contraindications (Must Not Use)

Desloratadine is formally contraindicated in patients with a known hypersensitivity (allergy) to the active substance, to any of the product’s inactive ingredients (excipients), or to the parent compound, Loratadine. Additionally, patients with rare hereditary problems of galactose intolerance should not use lactose-containing tablet formulations.

Conditional Use and Restrictions

Use requires caution and potential dosage adjustment in patients with severe hepatic (liver) impairment or severe renal (kidney) insufficiency due to altered drug clearance. Administration also requires caution in patients with a medical or familial history of seizures. The medicine is not recommended for use during pregnancy or breastfeeding.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Desloratadine details specific pharmacokinetic and pharmacodynamic interaction patterns, but designates no combinations as strictly contraindicated.

Pharmacokinetic and Exposure Modification

Co-administration with several potent inhibitors, including Ketoconazole, Erythromycin, Cimetidine, and Fluoxetine, results in increased plasma concentrations (AUC and C max) of Desloratadine and its active metabolite. Critically, government-authorized clinical trials documented that these increases in exposure were not associated with clinically relevant changes in the safety profile.

Population-Specific and Substance Interactions

Category Regulatory Outcome
Population-Specific Increased exposure (AUC) is formally documented in patients with hepatic impairment (approx. 2.4-fold) and severe renal impairment (approx. 2.5-fold), representing intrinsic interaction considerations for these groups.
Alcohol (Ethanol) Clinical trials showed no potentiation of alcohol's performance-impairing effects. However, caution is noted due to post-marketing reports of alcohol intolerance.
Food and Timing Desloratadine may be taken with or without a meal. No mandatory timing or separation rules are documented in the official regulatory information.

Mechanism of Action

How Desloratadine Works

Desloratadine functions as a selective peripheral H1-receptor antagonist, acting within domains involving receptor-mediated signaling. This tricyclic histamine blocker modulates key pathways associated with heightened physiological responses by specifically blocking the binding of endogenous histamine to the H1 receptor. This antagonism limits the impact of excessive mediator activity, resulting in the restriction of histamine-induced biological activity.

Beyond direct receptor blockade, desloratadine influences secondary inflammatory processes. The compound modifies early molecular steps by suppressing the release of other pro-inflammatory chemical mediators from mast cells and basophils, including leukotrienes and prostaglandins. This systemic effect maintains reduced levels of pathway activation within targeted cellular systems. Furthermore, its mechanism extends to the nuclear factor kappa B ( NF-kappa B) pathway and interleukin-6 ( IL-6) production, leading to pathway-specific modifications that influence general inflammatory signaling.

Dosage and Administration Information

Official Administration Guidelines

Desloratadine is for oral use and is administered once daily without regard to the timing of meals. It is available in various official forms, including film-coated tablets, orally disintegrating tablets (ODT), and an oral solution (syrup).

Labeled Dosage Schedule

Age Group Recommended Daily Dose Form (Typically)
Adults & Adolescents (≥ 12 years) 5 mg once daily Tablet or Oral Solution
Children 6 to 11 years 2.5 mg once daily ODT or Oral Solution
Children 12 months to 5 years 1.25 mg once daily Oral Solution
Children 6 to 11 months 1.0 mg once daily Oral Solution

Preparation and Special Conditions

  • Oral Solution: The dose should be measured using a calibrated measuring dropper or syringe to ensure accuracy; household teaspoons must not be used.
  • Orally Disintegrating Tablets (ODT): These tablets must be placed on the tongue immediately after removing them from the blister package and allowed to dissolve before swallowing with saliva or water.
  • Missed Dose: If a dose is missed, take it as soon as it is remembered. However, if it is nearly time for the next scheduled dose, the missed dose should be skipped to avoid taking a double dose.

Population-Specific Instructions

For adult patients with renal (kidney) or hepatic (liver) impairment, an initial starting dose of 5 mg every other day is recommended based on pharmacokinetic data to allow for adequate drug clearance.

Recent Clinical Evidence

Desloratadine: Recent Clinical Evidence

Desloratadine is a second-generation, non-sedating antihistamine used to address symptoms associated with allergic rhinitis and chronic idiopathic urticaria (hives). Research confirms its classification as a selective peripheral H1-receptor antagonist, which means it works by blocking histamine's effects without easily crossing the blood-brain barrier.


Efficacy and Indications

Clinical trials have established desloratadine's use in providing relief from symptoms such as sneezing, runny nose, itching, and watery eyes associated with seasonal and perennial allergic rhinitis. Studies show that the drug provides symptom relief within the first day of treatment. For patients with chronic idiopathic urticaria, research indicates that desloratadine helps reduce the size and number of hives and associated itching.


Pharmacokinetic and Safety Profile

Desloratadine is the major active metabolite of loratadine. Its half-life averages around 27 hours, supporting its designation as a once-daily treatment. Research evaluating its safety profile has shown that, at recommended doses, it is well-tolerated. The incidence of common adverse effects, such as dry mouth, fatigue, and headache, is generally considered comparable to that observed with a placebo in clinical trials.

Indication Studied Primary Endpoint Observed
Allergic Rhinitis (AR) Reduction in Total Symptom Score (TSS)
Chronic Idiopathic Urticaria (CIU) Reduction in Pruritus (Itching) Severity

Frequently Asked Questions (FAQ)

Common questions about Desloratadine (FAQ)


Q: Does Desloratadine cause drowsiness or make you sleepy?

Desloratadine is classified as a non-sedating antihistamine, and most individuals in clinical studies did not experience drowsiness or sedation. However, drowsiness and somnolence (sleepiness) are documented adverse reactions reported at very low frequencies in official product information.


Q: Are there any specific foods or drinks that should be avoided when taking Desloratadine?

Official regulatory information indicates that the absorption of Desloratadine is unaffected by food, meaning it can be taken with or without a meal. Clinical studies also indicate that grapefruit juice does not significantly impact the bioavailability of Desloratadine.


Q: Are there any warnings about driving or operating machinery while taking Desloratadine?

Based on clinical trial data, Desloratadine has been found to have no or negligible influence on the ability to drive or use machines. However, official product information recommends that individuals be aware of their response before engaging in tasks requiring concentration, as personal responses may vary.


Q: Is Desloratadine the same as Claritin (Loratadine)?

No, they are not exactly the same. Desloratadine is considered the primary active form (active metabolite) of the older antihistamine Loratadine. Hypersensitivity (allergy) to either substance is a formal contraindication for using Desloratadine.


Q: Can Desloratadine be used for an allergic reaction to food?

Desloratadine is officially approved for the relief of symptoms associated with seasonal and perennial allergic rhinitis (e.g., hay fever) and chronic idiopathic urticaria (hives). The officially labeled indications do not include the treatment of acute food allergy.


Q: Does Desloratadine have any impact on the central nervous system?

While classified as a non-sedating drug with a reduced ability to cross into the central nervous system (CNS), adverse reactions documented in official safety profiles which affect the nervous system include dizziness, insomnia, somnolence, and seizures.


Q: Is Desloratadine known to cause weight gain?

Weight increased is a documented adverse reaction reported during post-marketing surveillance, a period when a medicine is monitored after approval. Its frequency is officially classified as Not known because it has not been conclusively established through controlled clinical trials.


Q: Are there any severe or rare side effects of Desloratadine I should know about?

Official product information documents serious adverse reactions with a Very Rare frequency (less than 1 in 10,000 people). These include severe hypersensitivity reactions (such as Anaphylaxis and Angioedema), as well as Hepatitis, Jaundice, and Seizures.


Q: Is Desloratadine available over the counter, or is it prescription only?

The prescription status of Desloratadine varies by region. For example, in the United States, the brand product (Clarinex) is typically available by prescription only. In contrast, in some other countries, generic versions may be available for purchase over the counter.


Q: Can Desloratadine affect or interfere with sleep?

Yes. Insomnia (difficulty sleeping) is listed as a documented adverse reaction in official safety documents under Nervous System Disorders.


Q: Can Desloratadine be taken at the same time as cold and flu medicine?

Desloratadine is available in certain fixed-dose combination products with ingredients commonly found in cold and flu medicines, such as decongestants. This indicates that co-administration is acceptable under specific formulation guidelines.


Q: If I have kidney problems, can I still take Desloratadine?

Use in adult patients with severe renal (kidney) impairment requires dosage consideration due to the way the body processes the medicine. Official product information indicates that a modified starting regimen may be recommended for adult patients with severe kidney problems to allow for adequate drug clearance.


Q: Is Desloratadine a steroid?

No. Desloratadine is classified in official regulatory documents as a potent, long-acting second-generation antihistamine that acts as a selective H1-receptor antagonist. It is not classified as a corticosteroid (a steroid medicine).


Q: What does 'metabolite' mean when describing Desloratadine?

The term metabolite refers to the fact that Desloratadine is the main active form of the older medicine, Loratadine. This classification means the substance is already in its fully active state upon administration.


Q: Is Desloratadine safe for older adults (seniors)?

Desloratadine is approved for use in adults (individuals 12 years of age and older). Official documents note that specific cautions and potential dose adjustments are necessary for adult patients who also have severe kidney or liver impairment, as these conditions are factors in drug clearance.


Q: Can Desloratadine be taken on an empty stomach?

Yes. Desloratadine may be taken with or without food. Clinical studies indicate that the drug’s absorption and bioavailability are not significantly affected when it is administered under fasted (empty stomach) conditions.


Q: Does Desloratadine affect blood pressure?

Although the incidence is classified as Very Rare, post-marketing reports have documented cardiac disorders including Tachycardia (fast heartbeat) and QT prolongation (an electrical change in the heart). Official safety reviews monitor this potential risk.


Q: Is it possible to be allergic to Desloratadine itself?

Yes. Desloratadine is formally contraindicated for patients with a known hypersensitivity (allergy) to the active substance, any of the product’s inactive ingredients (excipients), or the parent compound, Loratadine.


Q: Has Desloratadine been studied in children under the age of 2?

Yes. Safety and efficacy have been established for children 6 months of age and older for specific indications. Safety studies were conducted across the pediatric population, including infants and toddlers aged 6 to 23 months.


Q: What percentage of people experience side effects from Desloratadine?

In clinical trials for the recommended 5 mg daily dose, undesirable effects (adverse events) with Desloratadine were reported in 3% of patients in excess of those treated with a placebo. This figure is used in official summaries to describe the general safety profile.


Q: Does Desloratadine cause changes in mood or anxiety?

Abnormal behaviour is listed as an adverse reaction in the official product information, but its frequency is classified as Not known (based on post-marketing reports). This is the only adverse effect documented related to changes in behavior or mood.


Q: Is it known if Desloratadine interacts with grapefruit juice?

Clinical studies have shown that the oral absorption and effectiveness of Desloratadine are unaffected by the consumption of grapefruit juice.


Q: Is it necessary to stop taking Desloratadine before an allergy test?

Yes. Antihistamines, including Desloratadine, can interfere with the results of allergy skin tests. Patient guidance based on medical protocol generally recommends stopping the medicine several days before the allergy test is performed.


Q: How common are side effects like dry mouth or headache?

Dry mouth and headache are the most frequently documented adverse reactions for Desloratadine, classified as Common (affecting 1% to < 10% of patients). These effects are documented as common in clinical trials and are typically mild.

How should Desloratadine be stored and disposed of?

Storage and Disposal of Desloratadine

Desloratadine requires specific storage conditions to maintain its stability and quality. Tablets must be kept at controlled room temperature, which is between 20 C and 25 C (68 F and 77 F). The product must be protected from moisture, often by remaining in its original package, and liquid forms should be protected from light and must not be frozen. All forms of desloratadine must be kept out of the sight and reach of children.

Expired or unused desloratadine must be disposed of according to local requirements. The medicine should not be thrown into wastewater or household waste. Recommended disposal methods include drug take-back locations or prepaid mail-back envelopes.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Desloratadine found in:

A-Z Index: